Nutritional Changes and Micronutrient Supply in Patients with Phenylketonuria Under Therapy with Tetrahydrobiopterin (BH4) by A. G. Thiele et al.
RESEARCH REPORT
Nutritional Changes and Micronutrient Supply in Patients
with Phenylketonuria Under Therapy with
Tetrahydrobiopterin (BH4)
A.G. Thiele • J.F. Weigel • B. Ziesch • C. Rohde •
U. M€utze • U. Ceglarek • J. Thiery • A.S. M€uller •
W. Kiess • S. Beblo
Received: 12 April 2012 /Revised: 22 August 2012 /Accepted: 6 September 2012 /Published online: 17 October 2012
# SSIEM and Springer-Verlag Berlin Heidelberg 2012
Abstract Background: Since 2008 patients with BH4-
sensitive phenylketonuria can be treated with sapropterin
dihydrochloride (Kuvan®) in addition to the classic
phenylalanine (Phe) restricted diet. The aim of this study
was to evaluate the nutritional changes and micronutrient
supply in patients with phenylketonuria (PKU) under
therapy with tetrahydrobiopterin (BH4).
Subjects and Methods: 19 children with PKU (4–18
years) and potential BH4-sensitivity were included, 14
completed the study protocol. Dried blood Phe concen-
trations as well as detailed dietary records were obtained
throughout the study at preassigned study days.
Results: Eight patients could increase their Phe tolerance
from 629  476 mg to 2131  1084 mg (P ¼ 0.006)
under BH4 while maintaining good metabolic control (Phe
concentration in dried blood 283  145 mM vs. 304  136
mM, P ¼ 1.0), therefore proving to be BH4-sensitive. They
decreased their consumption of special low protein products
and fruit while increasing their consumption of high protein
foods such as processed meat, milk and dairy products.
Intake of vitamin D (P ¼ 0.016), iron (P ¼ 0.002),
calcium (P ¼ 0.017), iodine (P ¼ 0.005) and zinc
(P ¼ 0.046) significantly declined during BH4 treatment
while no differences in energy and macronutrient supply
occurred.
Conclusion: BH4-sensitive patients showed good meta-
bolic control under markedly increased Phe consumption.
However, the insufficient supply of some micronutrients
needs consideration. Long-term multicenter settings with
higher sample sizes are necessary to investigate the changes
of nutrient intake under BH4 therapy to further evaluate
potential risks of malnutrition. Supplementation may
become necessary.
Introduction
Phenylketonuria (PKU, OMIM 261600), one of the most
common inborn errors of metabolism, is caused by
mutations in the gene encoding phenylalanine hydroxylase
(PAH, EC 1.14.16.1), leading to deficient enzyme activity.
More than 500 mutations in the PAH gene have been
identified (http://www.PAHdb.mcgill.ca). PAH is primarily
expressed in the liver, its activity depending on tetrahy-
drobiopterin (BH4) as a cofactor. The enzyme catalyses the
irreversible hydroxylation of phenylalanine (Phe) to tyro-
sine (Tyr). In PAH deficient patients, Phe accumulates in
blood and tissues while a deficiency of Tyr develops. In
untreated patients, this results in severe, irreversible
psychomotor retardation. Newborn screening and initiation
of dietary treatment within the first weeks of life nowadays
allow for a normal neurocognitive development (Scriver
et al. 1998). The treatment of PKU consists in dietary
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restriction of Phe and therefore natural protein and a
supplementation with Phe free amino acid mixtures
(AAM). Next to essential amino acids except for Phe the
AAM contain energy, carbohydrates and fat as well as
vitamins, minerals and trace elements as currently recom-
mended by the national councils (for the German speaking
countries, DACH 2000). The extent of Phe restriction
depends on the patients` individual Phe tolerance, which
depends on residual PAH activity as well as the patients`
age and weight (Scriver et al. 1998). Phe tolerance is
determined by regularly monitored dried blood Phe
concentration. Protein rich foods such as meat or dairy
products, which are also important sources for other
nutrients such as iron, vitamin B12 or calcium, must be
strictly avoided. Most natural food has to be replaced by
special low protein products.
Phe restriction and AAM supply are well established as
an efficient and safe treatment for PKU patients. However,
this therapy remains a great challenge and burden for the
patients and their families. In the classical treatment of
PKU it is necessary to plan meals exactly and to calculate
the Phe content of all foods. Only recently, some
specialized centres allow the unrestricted consumption of
fruits and vegetables under certain conditions (Macdonald
et al. 2003; Rohde et al. 2012; Zimmermann et al. 2012).
However, the individual Phe tolerance has to be respected.
Moreover, the AAM have an unpleasant taste. As a
consequence patients often show a low diet adherence,
particularly older children and adolescents (Macdonald
2000; Macdonald et al. 2010). Especially during adoles-
cence many patients drop out of specialized care (M€utze
et al. 2011). Discontinuation of dietary treatment bears a
high risk of nutrient deficiencies, cognitive and emotional
dysfunction as well as behavioral problems. Therefore, life-
long diet is strongly recommended (Stemerdink et al. 2000;
Burgard et al. 1997; Weglage et al. 1992).
In recent years, BH4 supplementation has been inves-
tigated as a new therapeutic tool in PKU treatment. It was
shown that in some PKU patients BH4 enhanced the
residual PAH activity and partially restored Phe oxidation
(Muntau et al. 2002). As a result, blood Phe concentrations
decrease while Phe tolerance can increase up to 2- to 3-fold
(Hennermann et al. 2005; Lambruschini et al. 2005; Burlina
and Blau 2009; Trefz et al. 2009). This now allows some
patients to consume protein rich foods. The dosage of Phe
free AAM can be reduced. Due to the higher Phe tolerance,
quality of life as well as therapy adherence may be
enhanced (Ziesch et al. 2012). However, BH4 monotherapy
seems to be sufficient in only few cases (Lambruschini
et al. 2005).
Available reports on BH4 supplementation have focused
on the identification of patients who may benefit from BH4,
and the quality of metabolic control (Bélanger-Quintana
et al. 2005; Fiori et al. 2005; Burton et al. 2007, 2010;
Burlina and Blau 2009; Trefz et al. 2009). The small
number of studies investigating the nutrition of PKU
patients under BH4 treatment revealed heterogeneous
results (Lambruschini et al. 2005; Singh et al. 2010).
The aim of this study was to investigate eating habits of
BH4-sensitive patients under BH4 therapy compared to the
classical Phe restricted diet. We evaluated food and nutrient
intake in order to examine whether BH4 treated PKU
patients are adequately supplied with critical nutrients
under relaxed dietary conditions.
Study Design
This open, monocentric, prospective intervention trial
follows the principles of the Declaration of Helsinki and
ICH/GCP. It was approved by the University of Leipzig’s
ethics committee (registration-number 087-2009-
20042009). All included patients and/or their guardians
gave written informed consent.
Inclusion was restricted to patients aged 4–18 years with
PKU and potential BH4 sensitivity. Patients with a BH4
deficiency as well as additional diseases or abnormal signs
in the general or neurological examination, a need for
concomitant medication except the Phe free AAM, an
implementation of other diets except the Phe restricted diet
and an existing or planned pregnancy were excluded.
The study design is shown in Fig. 1. In each of the four
study periods the patients were asked to send dried blood
samples and dietary records to the hospital on preassigned
study days.
Study period 1 consisted in the reevaluation of the
current dietary treatment by review of Phe concentrations in
dried blood one year prior to enrolment and determination
of current Phe tolerance using a 3 day dietary record (days
–3 to 0). In study period 2 (days 0 to 14), the patients were
instructed to double their daily Phe intake from natural
protein (from any food) to achieve Phe concentrations
 600 mmol/l. No standardized meals were given through-
out the study. The intake of the Phe free AAM was
continued. Dietary records were performed three times a
week and dried blood samples for analyses of Phe
concentrations were obtained. In study period 3 (day 14
to 42), the patients received sapropterin dihydrochloride
(Kuvan®, Merck Serono) at 20 mg per kg body weight
daily, administered as single oral dose in the morning, while
continuing the doubled Phe intake. On day 42, patients
were defined as BH4-sensitive if they showed a reduction in
Phe concentration of  30 % and/or an increase of Phe
consumption by  100 % while Phe concentrations
remained within the therapeutic range. All other patients
were classified as BH4-resistant. During study period
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4 (days 43 through 90 ¼ follow-up), BH4-sensitive patients
continued BH4 treatment. During follow up, every actual
Phe concentration was evaluated and followed by personal
contact with the patient or the parents to advise on further
increase of Phe consumption. Once the patients had reached
an adequate protein consumption from natural foods
(DACH 2000) AAM dosage was reduced.
Subjects and Methods
Subjects
A total of 41 patients (4–18 years), treated at the outpatient
clinic for inborn metabolic diseases at the University
Hospital in Leipzig, Germany, were screened for participa-
tion. They were tested for potential sensitivity to BH4 by
determination of their PAH mutation and reevaluation of the
neonatal BH4-test. In 20 of the patients BH4-sensitivity
seemed to be implausible. The other (n ¼ 21), including
those whose results were incomplete, were offered to test
BH4 (as sapropterin dihydrochloride, Kuvan
®) as a potential
additional treatment. Two of the patients declined participa-
tion. Nineteen patients were included into the study.
Of these, 18 completed the protocol. One patient refused
to take the medication and terminated study participation.
Four other patients ignored essential parts of the study
protocol and had to be excluded from the analysis. All
participants had been diagnosed with PKU by newborn
screening and dietary treatment had been initiated within
the first 2 weeks of life. All but four underwent a test for
BH4-sensitivity when first diagnosed. None of them
showed a deficiency in tetrahydrobiopterin (Kaufman
et al. 1978; Blau et al. 2011). All patients were regularly
followed in the outpatient clinic for inborn metabolic
diseases and their reliable adherence to a Phe restricted
diet had been recorded. The dosage of substitution with
synthetic amino acids followed the current recommenda-
tions for protein intake in children (DACH 2000) with an
added surplus of 20 % to account for possible differences in
biological value relative to natural protein.
Methods
Assessment of Plasma Phe Concentrations
Patients took samples of capillary whole blood on filter
paper at preassigned study days. All parents were familiar
with the proper technique, having been trained during the
patients` newborn period. Phe and Tyr concentrations in
dried blood were determined by liquid chromatography/
tandem mass spectrometry (LC-MS/MS) as previously
described (Ceglarek et al. 2002).
Assessment of Food and Nutrient Intake
The patients and/or their guardians performed dietary
records throughout the study on preassigned study days.
All foods and beverages, including special low protein
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Fig. 1 Study design of BH4-intervention trial in PKU patients. BH4 tetrahydrobiopterin, PAH phenylalanine hydroxylase, Phe phenylalanine,
DB dried blood, DR dietary record
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All ingested food was allocated to the following food
groups: bread and cereal products, potatoes/ rice and pasta,
vegetables, fruit, milk and dairy products, other food of
animal origin (meat and processed meat, fish, egg), edible
fat (butter, margarine, oil), sweets and snacks, special low-
protein products. This classification was chosen according
to the recommendations for age-based food consumption
issued by the German Research Institute of Child Nutrition
(Kersting and Alexy 2005).
Nutritional analysis was performed using the Food and
Control Management System “Di€at 2000” based on the
updated version of the Bundeslebensmittelschl€ussel (Hart-
mann 2009). Additional information on AAM, low protein
foods as well as other processed foods provided by the
manufacturer was added to the database. Besides Phe intake
(mg/day) the following nutrients were calculated as
percentage of regular daily allowance, recommended for
the German speaking countries (DACH 2000): energy,
protein, carbohydrate, fat, vitamin C, vitamin D, vitamin
B12, iron, calcium, iodine and zinc.
Mean nutrient supply and food consumption of BH4-
sensitive patients under the new therapeutic regime was
compared to the classical dietary treatment and to the
current recommendations for nutrient intake (DACH 2000).
In addition, mean nutrient supply was compared to data
from a cohort of age-matched healthy German children
(Mensink et al. 2007).
Statistical Analysis
All procedures were performed using SPSS for Windows
17 (SPSS Inc., Chicago, Illinois).
To reduce the number of variables, laboratory data from
each study period were averaged and used for analyses. If
normality of distribution could be assured, longitudinal
changes in nutrient supply over the four study periods were
analysed by Wilk’s multivariate analysis of variance (MAN-
OVA) with “time” as the within-subject factor with four
levels (study periods 1 through 4). If Wilk’s analysis yielded
a significant effect of “time”, this was followed by repeated
(sequential) contrasts to locate pairs with significant changes
over time. In analogy, data that were not normally distributed
were analysed by Friedman test and Wilcoxon test.
Significance was accepted for P < 0.05. Data are given
as mean  standard deviation (SD) unless otherwise stated.
Results
Patient Characteristics
A total of 14 patients (6 females, 8 males) could be
considered in the analysis of metabolic control and Phe
intake. All of them had a normal body weight with a mean
BMI-SDS of 0.21  1.0. In one of these patients no data of
nutrient supply under classical therapy except for Phe
consumption were available. Thus, this patient had to be
excluded from the nutrition analyses. No adverse events
were observed throughout the study.
Metabolic Control and Phe Consumption
The data of Phe concetration in dried blood, Phe and
natural protein consumption are presented in Table 1. Over
the last year prior to study entry all included patients
showed good metabolic control. Eight patients proved to be
BH4-sensitive. In the other six patients, BH4 therapy was
not effective. Only BH4-sensitive patients stayed on BH4
therapy during follow-up. They continued to show good
metabolic control with stable dried blood Phe concentra-
tions within the therapeutic range that did not differ from
study entry (see Table 1, P ¼ 1.0).
In BH4-resistant patients we found a slight increase of
Phe intake and a significantly higher Phe concentration in
dried blood during follow-up compared to study entry
(621 mmol/l  117 vs 474 mmol/l  141 at study entry;
P ¼ 0.003). It took them another three months to regain the
original metabolic control (data not shown).
Food Consumption of BH4-Sensitive Patients
Figure 2 shows the food consumption of BH4-sensitive
patients under classical dietary treatment compared to BH4
therapy. The serving sizes of consumed food remained
unchanged throughout the study. In contrast, remarkable
changes with regard to food choice could be observed.
Before study entry all BH4-sensitive patients followed a Phe
restricted diet, having some characteristics of a vegan diet.
Due to the partially very low Phe tolerance they mainly
consumed fruit and vegetables. A further important share of
total food consumption was spent on special low protein
products, mainly low protein sausages, bread, pasta, rice,
potato products. In addition, the patients consumed a
relatively large amount of sweets (in particularly jelly beans),
jelly and sweet powdered instant drinks. No differences
compared to BH4-resistant patients could be revealed.
From study period 2 onwards all BH4-sensitive patients
increased their consumption of foods with a higher protein
content such as bread, pasta, rice and dairy products as well
as meat, egg and fish. The mean fruit and vegetable
consumption under BH4 administration dropped compared
to classical treatment, but no significance was found
(P ¼ 0.274 and P ¼ 0.139, respectively). In contrast, the
intake of edible fats as well as sweets and snacks remained












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Macronutrient Intake of BH4-Sensitive Patients
Under classical treatment (study period 1) as well as in
study periods 2 and 3 all BH4-sensitive patients regularly
took an AAM. During follow-up six of the eight BH4-
sensitive patients could end any AAM supply. In the other
two BH4-sensitive patients the dosage could be reduced.
Under classical treatment (study period 1) total protein
intake (sum of synthetic protein from AAM and intact
protein from natural food) was markedly above the
recommended range (165  38 %). Total protein intake
remained stable throughout the study, but the proportions of
synthetic and natural protein changed. In study period 1 the
intake of synthetic protein from AAM was 120  28 %
compared to 45  13 % from intact natural protein of the
current recommendation (DACH 2000). By doubling the
Phe intake in study periods 2 and 3 the patients ingested
twice as much natural protein and further increased this
amount during follow-up. Under BH4 therapy during
follow-up, the total protein intake was similar to that of
classic treatment (P ¼ 0.292). However, the patients now
consumed 142 % of the recommended protein as intact
protein from natural foods and only 12 % as synthetic
protein from AAM.
Under classical treatment BH4-sensitive patients showed
a carbohydrate intake below the current recommendations
(93  22 %; DACH 2000), which even further decreased
during the other study periods (during follow-up 70  18 %,
P ¼ 0.032). The mean fat intake was stable over the course
of the study, but lower than the recommendations
(81  25 % throughout the study).
Micronutrient Intake of BH4-Sensitive Patients
Figure 3 shows the supply of selected micronutrients of
BH4-sensitive patients under BH4 therapy (study period 4)
as well as under classical treatment. In addition the data are
compared to data from aged-matched healthy German
children (Mensink et al. 2007).
Under the Phe restricted diet (study period 1) overall
micronutrient intake except for vitamin C was adequate. The
highest percentage of vitamins and minerals derived from
AAM and only a small amount from natural food. During
study periods 2 and 3, mean total supply of vitamin D, vitamin
B12, iron, calcium, iodine and zinc remained stable and no
significant differences occurred compared to study period 1
as the patients still consumed the original dose of AAM.
In patients who reduced or stopped AAM intake during
follow-up (study period 4), the micronutrient supply
dropped markedly below the current recommendations
(DACH 2000) and deteriorated compared to the classic
treatment. The differences were significant for vitamin D,
iron, calcium, iodine and zinc. Considering the vitamin C
content of Kuvan® (5 mg vitamin C per 100 mg sapropterin
dihydrochloride), total vitamin C supply did not differ
between study periods 1 and 4 (P ¼ 1.0). However, due to
a reduced fruit and vegetable intake, BH4-sensitive patients
consumed a lower amount of vitamin C from natural foods
compared to classical dietary treatment.
Comparing the results to data from age-matched healthy
German children (Mensink et al. 2007) several differences
could be noted (Fig. 3). In general, healthy German
children aged 6 to 17 years almost met the recommenda-
tions for all investigated micronutrients except for vitamin
D and iodine. Under classical dietary treatment, the BH4-
sensitive PKU patients showed a higher mean intake of
vitamin D, iron, calcium and iodine, but a lower mean
intake of vitamin C and vitamin B12. Under BH4 treatment
the supply of almost all micronutrients proved to be
markedly lower compared to the healthy German children.
Discussion
The study presented here investigated metabolic control and
eating habits, including food and nutrient supply, of BH4-
sensitive PKU patients. BH4-sensitive patients could
increase their Phe tolerance by 100 % or more while dried
blood Phe concentrations remained within the therapeutic
range. In comparison to the classical dietary treatment the
patients consumed more protein rich natural foods. In six of
the BH4-sensitive patients the AAM administration could
be stopped. Two of the BH4-sensitive patients further
needed some AAM. While mean total protein intake did
not change compared to the classical dietary treatment, the
mean intake of carbohydrate, energy and also of some
micronutrients declined and dropped below the current
recommendations (DACH 2000).
Under the new therapeutic regime, the BH4-sensitive
patients could increase their Phe tolerance and consumed
more protein rich foods. In contrast, the markedly declined
fruit and also the slightly reduced vegetable intake must be
considered as critical, since they are important sources of
vitamins, minerals, trace elements, phytochemicals and dietary
fibre. Several factors may explain this phenomenon. Due to
the increased consumption of protein rich food, patients may
feel satisfied earlier, reducing their desire for more food.
Furthermore, the classical Phe restricted diet quite likely does
not reflect the true food preferences of our patients.
In general, factors influencing food choice are very
complex, including socio-economic components as well as
psychological aspects (Zabinski et al. 2006; Elfhag et al.
2008). Moreover, parents´ eating habits are an important
factor influencing their children’s choice of healthy or less
healthy foods (Kremers et al. 2003; De Bourdeaudhuij et al.
2008).
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Interestingly, our patients did not realise their markedly
decreased fruit consumption. They were only aware of and
enjoyed the possibility to consume protein rich foods like
meat or dairy products. Over a longer term these patients
are at risk to adopt some of the bad eating habits of healthy
German children (Mensink et al. 2007). The study period
has certainly been too short to completely develop a new
dietary regime, especially with regard to seasonal differ-
ences in food choice. Extending the study would have
permitted the patients to slowly accustom to a liberalized
nutrition. However, this requires a high adherence to the
study protocol by the patients and it is associated with
higher costs. Reevaluating the nutrient intake at least 6
months after introduction of BH4 treatment and identifying
the new correct Phe tolerance would be advisable.
The changed food choice of BH4-sensitive patients
resulted in changes of macro- and micronutrient supply.
Under classical dietary treatment the patients` mean nutrient
intake was still adequate except for fat, total energy and
vitamin C. Under BH4 therapy their supply of carbohy-
drates and most of the investigated micronutrients dropped
below the recommended range (DACH 2000). The mean
total protein intake, however, was sufficient and compara-
ble to classical dietary treatment. This observation is in
accordance with data from a recent study (Singh et al.
2010). Likewise, the fat supply did not change compared to
classical dietary treatment, but stayed below the recom-
mendations (DACH 2000). A low fat intake in PKU
patients under Phe restricted diet has already been described
(Schulz and Bremer 1995, Rohde et al. 2012). Many of the
protein rich foods, which must be avoided in the PKU diet,
are simultaneously sources rich in fat. This is especially
true for meat, processed meat and dairy products. Although
the BH4-sensitive patients increased their consumption of
these foods they did not meet the recommendation for fat
supply.
Under BH4 therapy the carbohydrate intake declined and
dropped below the current recommendations (DACH
2000). Taken together, the BH4-sensitive patients did not
meet the recommendations for the energy supply in healthy
children (DACH 2000). Although none of the patients was
underweight or growth retarded, a regular examination of
energy – and macronutrient supply is strongly recommen-
ded, in particular when switching from classical dietary
treatment to BH4 therapy with a liberalized diet.
During the Phe restricted diet (study period 1) some of
the patients showed a vitamin C supply slightly below the
recommended range (DACH 2000). None of them took an
AAM containing vitamin C. As a consequence of reduced
fruit and vegetable consumption under the BH4 treatment,
the vitamin C supply of our patients further declined. Only
taking into account the vitamin C content of Kuvan®, there
were no differences compared to study period 1. However,
a special supplementation of vitamin C seems not to be
necessary for PKU patients, as the most fruit and
vegetables, the main sources for vitamin C, are low in
protein and could be consumed in adequate amounts.
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Fig. 2 Food consumption of BH4-sensitive patients on classical
dietary treatment (left bar) compared to BH4 therapy during follow-up
(right bar). Shown are the shares of food groups (%) of total food
consumption (*significant difference between period 1 and 4: bread
(P ¼ 0.022), dairy products (P ¼ 0.002); potatoes, pasta and rice
(P ¼ 0.021), food of animal origin (meat, processed meat, fish, egg,
P ¼ 0.016); special low protein products (P ¼ 0.009))
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and vegetables does not impair the metabolic control in
PKU patients (MacDonald et al. 2003; Rohde et al. 2012;
Zimmermann et al. 2012). Hence, independent from the
therapeutic regimes (Phe restricted diet + AAM alone or in
combination with BH4) it should be the objective to
encourage the patients to eat more fruits as well as
vegetables, rather than supplementing vitamin C.
Following the stopped or reduced AAM administration,
the patients also showed an insufficient supply of some
other micronutrients, in particular of vitamin D, iron,
calcium, iodine and zinc. With respect to the long-term
outcome of this group of patients, an insufficient micronu-
trient supply should be avoided. This might be the reason
why some specialized centres still supply BH4-sensitive
patients with a relatively high amount of AAM despite the
fact that their pure protein supply from natural food is
adequate (Singh et al. 2010). It should be remarked that the
micronutrient content of all AAM is calculated according to
a very limited Phe tolerance. A reduction of AAM supply
under BH4 treatment without adapting eating habits
therefore bears the risk of an insufficient micronutrient
supply. On the other hand overdosing AAM in order to
supply adequate amounts of micronutrients may lead to
obesity. One could argue that even healthy German children
do not reach the currently recommended intake of several
micronutrients, especially vitamin D. However, their micro-
nutrient intake is still above that of the investigated children
with PKU. In addition vitamin D deficiency continuous to
be a common problem among otherwise healthy children.
Endogenous production, cleavage by sunlight and further
enzymatic modification into active vitamin D3 are not
satisfactory to prevent rickets. This even led to compulsory
vitamin D3 supplementation of dairy products in some
countries (Unuvar and Buyukgebiz 2010).
As a consequence a micronutrient supplement not
containing any protein, carbohydrate or fat should be
developed for these patients. Unfortunately specifically
developed supplements are only available in some
countries. Alternatively, the intake of an existing vitamin
and mineral supplement for healthy children is recommen-
ded at least for the period until eating habits change
completely towards an adequate supply from natural food.
In conclusion, the results of the study confirm that some
patients benefit from a BH4 therapy. Their Phe tolerance
increases markedly, allowing a relaxed diet containing more
protein rich food. Furthermore, BH4-sensitive patients do
no longer need special low protein products. Nevertheless,
BH4 supplementation with a relaxed diet currently bears the
risk of an imbalanced nutrition. Especially, with respect to
nutrition related diseases the potential micronutrient defi-
vitamin C from Kuvan®
AAM
food






































































Fig. 3 (a–b) Protein and micronutrient supply of BH4-sensitive
patients (n ¼ 7) under Phe restricted diet (upper bar) and under BH4
therapy during follow-up (middle bar) compared to age-matched
healthy German children (lower bar) as percent of DACH-RDA.
Shown are the shares of food and amino acid mixture (AAM) of the
total nutrient supply. The vitamin C content of Kuvan® was included
into the calculation. Under the Phe restricted diet all these patients
took an amino acid mixture while under BH4 therapy only two
patients took some (* significant differences in total micronutrient
supply in BH4-sensitive patients under Phe restricted diet compared to
BH4 therapy: P vitamin D ¼ 0.016; P iron ¼ 0.002; P calcium ¼ 0.017;
P iodine ¼ 0.005, P zinc ¼ 0.046)
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ciency needs consideration. Supplementation may become
necessary. Nutritional education seems to be important for
PKU patients under a BH4 therapy as the new dietetic
regime contradicts almost everything they were taught
before. To prevent deterioration of eating habits a close
follow-up of these patients by dieticians is recommended.
Long-term multicenter settings with a higher sample size
are necessary to further investigate the nutrient supply
under BH4 therapy and to satisfy the dietary requirements
of this special group of patients in the future.
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Take Home Message
Although BH4 therapy is an effective and helpful additional
treatment in some patients with PKU, changes in eating
habits and consequently insufficient supply of micronu-
trients has to be judged critically.
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